Home
Categories
EXPLORE
Music
True Crime
Comedy
Society & Culture
Education
Technology
History
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/f7/cf/2f/f7cf2f56-e17f-57b0-3042-59e7ae7bf355/mza_8305563713420802039.jpg/600x600bb.jpg
MitoAction Expert Series
MitoAction
100 episodes
8 months ago
Our monthly educational webinars feature guest speakers addressing topics important to the mito community, giving patients and families unprecedented access to leading clinical experts
Show more...
Science
Health & Fitness
RSS
All content for MitoAction Expert Series is the property of MitoAction and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Our monthly educational webinars feature guest speakers addressing topics important to the mito community, giving patients and families unprecedented access to leading clinical experts
Show more...
Science
Health & Fitness
https://episodes.castos.com/5ed548a1cb08d7-35811046/images/1988807/c1a-0q12-dm40wrqqcx0w-t59bwm.png
Expert Series: LCHADD Retinopathy Update: Moving Toward a Treatment
MitoAction Expert Series
1 hour 24 minutes 28 seconds
8 months ago
Expert Series: LCHADD Retinopathy Update: Moving Toward a Treatment
Having a better understanding of what things are associated with LCHADD retinopathy can provide insight towards developing treatment. During this presentation, Dr. Gillingham will provide an update on the current results of a natural history study of 40 patients with LCHADD. She will also discuss what factors are associated with retinal structure and function, and how blood biomarkers or genetics might be related. Lastly, Dr. Gillingham will update our FAOD community about her lab’s efforts to treat retinopathy in an LCHADD mouse.
MitoAction Expert Series
Our monthly educational webinars feature guest speakers addressing topics important to the mito community, giving patients and families unprecedented access to leading clinical experts